Schmidt B, Vegh P, Johnston M, Andrew M, Weitz J
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Thromb Haemost. 1993 May 3;69(5):418-21.
Disseminated intravascular coagulation (DIC) is usually diagnosed in sick infants who have prolonged clotting times, depletion of platelets and coagulation factors, and elevated levels of fibrin derivatives. However, the diagnostic accuracy of abnormal coagulation profiles in neonates at risk of DIC has been uncertain. Since DIC is characterized by activation of both the coagulation and fibrinolytic systems, the objective of this study was to determine whether coagulation screening tests correctly identify infants with biochemical evidence of increased thrombin and plasmin generation.
Non-surgical patients in a tertiary care nursery who were sick enough to require an indwelling arterial catheter for monitoring purposes, were enrolled in a prospective cohort study. Blood samples for thrombin/antithrombin III (TAT) complexes and the plasmin-derived fibrinopeptide B beta 1-42 were drawn 36 to 72 h after birth from a free-flowing arterial line. Platelet counts, D-Dimer levels, plasma fibrinogen concentrations and prothrombin times, expressed as International Normalized Ratios or INR, were measured at the same time.
One hundred patients were studied. Fifty-seven infants had elevated levels of TAT (> or = 4 micrograms/l) and B beta 1-42 (> or = 4 nmol/l). The sensitivities of platelets < 150 x 10(9)/l, D-Dimer > 500 ng/ml, fibrinogen < 1.5 g/l, and INR > 1.5 were 39%, 30%, 12%, and 11%, respectively. Corresponding specificities were 88%, 91%, 98%, and 95%.
Abnormal coagulation screens in sick newborn infants strongly support a diagnosis of DIC. However, normal screens do not exclude activation of the coagulation and fibrinolytic systems.
弥散性血管内凝血(DIC)通常在凝血时间延长、血小板和凝血因子消耗以及纤维蛋白衍生物水平升高的患病婴儿中被诊断出来。然而,有DIC风险的新生儿凝血指标异常的诊断准确性一直不确定。由于DIC的特征是凝血和纤溶系统均被激活,本研究的目的是确定凝血筛查试验能否正确识别出有凝血酶和纤溶酶生成增加生化证据的婴儿。
在一家三级护理托儿所中,病情严重到需要留置动脉导管进行监测的非手术患者被纳入一项前瞻性队列研究。出生后36至72小时,从自由流动的动脉管路采集血样,检测凝血酶/抗凝血酶III(TAT)复合物和纤溶酶衍生的纤维肽Bβ1-42。同时测量血小板计数、D-二聚体水平、血浆纤维蛋白原浓度以及以国际标准化比值(INR)表示的凝血酶原时间。
共研究了100名患者。57名婴儿的TAT(≥4微克/升)和Bβ1-42(≥4纳摩尔/升)水平升高。血小板<150×10⁹/升、D-二聚体>500纳克/毫升、纤维蛋白原<1.5克/升和INR>1.5的敏感性分别为39%、30%、12%和11%。相应的特异性分别为88%、91%、98%和95%。
患病新生儿异常的凝血筛查强烈支持DIC的诊断。然而,正常的筛查结果并不能排除凝血和纤溶系统的激活。